Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression

References

• Bentwich Z, Kalinkovich A, Weisman Z, Grossman Z. Immune activation in the context of HIV infection. Clin Exp Immunol 1998;111:1–2.
   PubMedGoogle Scholar
• Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169:3400–6.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, et al. CD4 + T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002;185:315–23.
   PubMedGoogle Scholar
• Sherman GG, Scott LE, Galpin JS, Kuhn L, Tiemessen CT, Simmank K, et al. CD38 expression on CD8(þ) T cells as a prognostic marker in vertically HIV-infected pediatric patients. Pediatr Res 2002;51:740–5.
   PubMedGoogle Scholar
• Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003;17:1881–8.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, et al. Immune activation set point during early HIV infection predicts subsequent CD4 + T-cell changes independent of viral load. Blood 2004;104:942–7.
   PubMed Web of Science ®Google Scholar
• Resino S, Bellón JM, Gurbindo MD, Muñoz-Fernández MA. CD38 expression in CD8 + T cells predicts virological failure in HIV type 1-infected children receiving antiretroviral therapy. Clin Infect Dis 2004;38:412–7.
   PubMed Web of Science ®Google Scholar
• Almeida M, Cordero M, Almeida J, Orfao A. Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1 + patients. Cytometry B Clin Cytom 2007;72:22–33.
   PubMedGoogle Scholar
• Resino S, Bellón JM, Gurbindo D, Ramos JT, León JA, Mellado MJ, Muñoz-Fernández MA. Viral load and CD4 + T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study. Clin Infect Dis 2003;37:1216–25.
   PubMedGoogle Scholar
• Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291–5.
   PubMed Web of Science ®Google Scholar
• Echaniz P, Arrizabalaga J, Iribarren JA, Cuadrado E. CD8 + CD38+ and CD8 + DR+ peripheral blood lymphoid subsets of HIV-infected intravenous drug abusers correlate with CD4 + cell counts and proliferation to mitogens. Cell Immunol 1993;150:72–80.
   PubMedGoogle Scholar
• Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4 + T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008;197:126–33.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, et al. Immune activation set point during early HIV infection predicts subsequent CD4 + T-cell changes independent of viral load. Blood 2004;104:942–7.
   PubMed Web of Science ®Google Scholar
• Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8 + T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4 + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:83–92.
   PubMedGoogle Scholar
• Koblavi-Dème S, Maran M, Kabran N, Borget MY, Kalou M, Kestens L, et al. Changes in levels of immune activation and reconstitution markers among HIV-1- infected Africans receiving antiretroviral therapy. AIDS2003;17(Suppl 3):S17–22.
   Google Scholar
• Rosenblatt HM, Stanley KE, Song LY, Johnson GM, Wiznia AA, Nachman SA, et al. Pediatric AIDS Clinical Trials Group 377 Study Team. Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection. J Infect Dis 2005;192:445–55.
   PubMed Web of Science ®Google Scholar
• Romeiro JR, Pinto JA, Silva ML, Eloi-Santos SM. Further evidence that the expression of CD38 and HLA-DR+ in CD8 + lymphocytes does not correlate to disease progression in HIV-1 vertically infected children. J Int Assoc Physicians AIDS Care (Chic) 2012;11:164–8.
   PubMedGoogle Scholar
• Prince HE, Jensen ER. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir Immune Defic Syndr 1991;4:1227–32.
   PubMed Web of Science ®Google Scholar
• Kestens L, Vanham G, Vereecken C, Vandenbruaene M, Vercauteren G, Colebunders RL, Gigase PL. Selective increase of activation antigens HLA-DR and CD38 on CD4 + CD45RO+ T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994;95:436–41.
   PubMedGoogle Scholar
• Ssewanyana I, Baker CA, Ruel T, Bousheri S, Kamya M, Dorsey G, et al. The distribution and immune profile of T cell subsets in HIV-infected children from Uganda. AIDS Res Hum Retroviruses 2009;25:65–71.
   PubMedGoogle Scholar
• Biancotto A, Iglehart SJ, Vanpouille C, Condack CE, Lisco A, Ruecker E, et al. HIV-1 induced activation of CD4 + T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood 2008;111:699–704.
   PubMedGoogle Scholar
• Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690–5.
   PubMed Web of Science ®Google Scholar
• Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol 1992;90: 376–82.
   PubMedGoogle Scholar
• Mocroft A, Bofill M, Lipman M, Medina E, Borthwick N, Timms A, et al. CD8+,CD38 + lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:158–62.
   PubMedGoogle Scholar
• Lepej SZ, Begovac J, Vince A. Changes in T-cell subpopulations during four years of suppression of HIV-1 replication in patients with advanced disease. FEMS Immunol Med Microbiol 2006;46:351–9.
   PubMedGoogle Scholar
• Arnó A, Ruiz L, Juan M, Zayat MK, Puig T, Balagué M, et al. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years. AIDS 1998;12: 697–704.
   PubMedGoogle Scholar
• Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, et al.; AIDS Clinical Trials Group Protocol 375 Team. Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002;16:1859–66.
   PubMed Web of Science ®Google Scholar
• Ondoa P, Koblavi-Dème S, Borget MY, Nolan ML, Nkengasong JN, Kestens L. Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d’Ivoire. Clin Exp Immunol 2005;140:138–48.
   PubMed Web of Science ®Google Scholar
• Lynne JE, Schmid I, Matud JL, Hirji K, Buessow S, Shlian DM, Giorgi JV. Major expansions of select CD8 + subsets in acute Epstein–Barr virus infection: comparison with chronic human immunodeficiency virus disease. J Infect Dis 1998; 177:1083–7.
   PubMedGoogle Scholar
• Komanduri KV, Luce JA, McGrath MS, Herndier BG, Ng VL. The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13: 215–26.
   PubMedGoogle Scholar
• García F, Plana M, Vidal C, Cruceta A, O’Brien WA, Pantaleo G, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999;13:F79–86.
   PubMed Web of Science ®Google Scholar
• Rosso R, Fenoglio D, Terranova MP, Lantieri F, Risso D, Pontali E, et al. Relevance of CD38 expression on CD8 T cells to evaluate antiretroviral therapy response in HIV-1-infected youths. Scand J Immunol 2010;71:45–51.
   PubMed Web of Science ®Google Scholar